High price counter attack! Six new drugs transfer amount explosion table of domestic pharmaceutical enterprises

Recently, the news that Zhengda Tianqing has transferred new hepatitis drugs to Johnson & Johnson with us $250 million has aroused heated discussion In fact, with the improvement of R & D capacity, domestic pharmaceutical companies have transferred new drug technology to multinational pharmaceutical companies at a high price for many times in recent years According to incomplete statistics of minenet, there are six transactions with an agreement price of US $100 million No1 transferor: Xinda biological partner: Lilly Pharmaceutical Co., Ltd.: > US $1 billion on October 12, 2015, Xinda biological pharmaceutical (Suzhou) Co., Ltd and Lilly pharmaceutical group of the United States reached three global development cooperation agreements on tumor immunotherapy bispecific antibody drugs, with the total milestone payment amount exceeding US $1 billion According to the cooperation agreement, Cinda biology and Lilly will cooperate to develop, produce and sell three new bispecific tumor immunotherapy antibodies, among which Cinda biology will cooperate to lead the development, production and sales of Chinese market, and Lilly will cooperate to lead the development, production and sales of foreign market All the three antibodies are based on PD-1 monoclonal antibody independently developed by Cinda biology, which is the most promising new type of bispecific tumor immunotherapy antibody Cinda bio will receive milestone payments totaling more than US $1 billion from Lilly; if the above antibodies are commercialized abroad, Cinda bio will also receive additional sales commissions and other payments No2 transferor: bioatla company partner: Pfizer amount: US $1 billion On December 7, 2015, Pfizer, an international pharmaceutical giant, signed a $1 billion strategic license and option agreement with bioatla Inc of the United States The two sides will integrate the conditional active biological antibody (CAB) technology of bioatla Co and the antibody drug conjugate (ADC) technology of Pfizer Co., Ltd to promote the development and commercialization of a new anti-tumor drug, conditional active biological drug conjugate (cab-adc) antibody It is worth noting that the institutional shareholder behind bioatla is the Shanghai Weihua Investment Center (limited partnership), a fund company under Peking University Weiming bioengineering Group Co., Ltd., which was established in April this year for the purpose of investing in bioatla, with a fund scale of $30 million invested in bioatla, and obtained no more than 20% equity of bioatla It is the largest institution of bioatla Shareholder No3 transferor: Hengrui pharmaceutical partner: Incyte company amount: 795 million US dollars on September 2, 2015, Hengrui pharmaceutical announced that the company and Incyte company of the United States reached an agreement in the United States, and the company will license the PD-1 monoclonal antibody (code "shr1210") project with independent intellectual property rights for tumor immunotherapy to Incyte company of the United States for compensation The license transfer will bring the company as much as 795 million US dollars Hengrui medicine has been engaged in the research and development of PD-1 monoclonal antibody since 2012 The company has applied for the domestic patent of shr1210 and PCT international patent In December 2014, the company was the first in China to submit a new drug clinical application, which is currently in the clinical stage to be approved Both parties agree that Hengrui pharmaceutical will license the PD-1 monoclonal antibody project for tumor immunotherapy with independent intellectual property rights to Incyte company in the United States for a fee, and Incyte company will obtain the global exclusive clinical development and marketing rights except for mainland China, Hong Kong, Macao and Taiwan Within 30 days after the signing of the agreement and receipt of Hengrui's receipt, Incyte will make a down payment of US $25 million to Hengrui However, there are certain preconditions for milestone payment If shr1210 is successfully listed in the European Union, the United States and Japan, Incyte in the United States will pay Hengrui a total of no more than 90 million US dollars of milestone payment for listing; if shr1210 has achieved excellent results in clinical trials abroad, Incyte in the United States will pay Hengrui 150 million US dollars of milestone payment for clinical excellence; the annual sales of shr1210 will reach different levels After the target, Incyte of the United States will pay Hengrui a cumulative sales performance milestone payment of no more than $530 million No4 transferor: Fosun Pharmaceutical partner: sellas amount: 388 million euros on October 23, 2013, Chongqing Fosun Pharmaceutical Research Co., Ltd., a subsidiary of Fosun Pharmaceutical Holdings, and sellas clinical Holding AG (hereinafter referred to as "sellas") formally signed a cooperation agreement in Greece Chongqing fuchuang will transfer its independent research and development rights to sellas concerning the development and sale of two compounds for type II diabetes and cancer: fotaglyptin benzoate and pan her inhibitors worldwide (except for the Chinese market), with a total transfer price of 388 million euros (about RMB 3248 million) In July 2014, Fosun Pharmaceutical and its parent company Fosun International announced that in October 2013, Fosun Pharmaceutical agreed to sell all rights, ownership and interests of two pharmaceutical intellectual property rights for 388 million euros (about 4.1 billion Hong Kong dollars), which was terminated due to the buyer's failure to pay the full amount on time Under the transfer agreement, the buyer is required to pay the consideration at different stages Yesterday, the buyer's cumulative consideration payable was 8 million euros, while the actual consideration paid was 1.5 million euros Fosun refers to the termination of the transfer agreement due to the buyer's breach of contract, and reserves the right to claim from the buyer for any loss that may be caused No5 transferor: Zhengda Tianqing partner: Johnson & Johnson Pharmaceutical Co., Ltd amount: US $253 million in January 2016, Zhengda Tianqing signed an exclusive license agreement with Johnson & Johnson Pharmaceutical Co., Ltd of the United States to license the international development right of an innovative hepatitis treatment drug outside the mainland of China to Johnson & Johnson According to the agreement, Johnson & Johnson will pay a total of US $253 million in down payment and mileage, as well as sales commission after listing The drug is a new small molecule antiviral oral drug, which can stimulate the patient's autoimmune function and produce the efficacy of clearing virus B It is reported that the project was started in 2013 and is currently in the pre clinical development stage It will apply for clinical trials in China in early 2016 Johnson & Johnson will carry out global development, production, registration and commercial promotion of the product outside China No6 transferor: kangfang biological partner: MSD amount: US $200 million in December 2015, Zhongshan kangfang biomedical Co., Ltd announced that the company and MSD signed a transfer agreement for new antibody drug project According to this Agreement: MSD will obtain the global exclusive development and promotion right of kangfang biological compound ak-107 Ak-107 is an immunocheckpoint blocking antibody discovered by kangfang biology in China and used for tumor immunotherapy According to the terms of the cooperation agreement, kangfangbio will receive an initial payment from MSD and a phased payment with a total price of US $200 million covering development and promotion (BIOON Com)